Search

Your search keyword '"Basappa, Naveen S."' showing total 264 results
Start Over Author "Basappa, Naveen S."
264 results on '"Basappa, Naveen S."'

1. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Takemura, Kosuke, Ernst, Matthew S., Navani, Vishal, Wells, J. Connor, Bakouny, Ziad, Donskov, Frede, Basappa, Naveen S., Wood, Lori A., Meza, Luis, Pal, Sumanta K., Szabados, Bernadett, Powles, Thomas, Beuselinck, Benoit, McKay, Rana R., Lee, Jae-Lyun, Ernst, D. Scott, Kapoor, Anil, Yuasa, Takeshi, Choueiri, Toni K., and Heng, Daniel Y.C.

Published
2024
Full Text
View/download PDF

2. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)

Author

Graham, Jeffrey, Ghosh, Sunita, Breau, Rodney H., Wood, Lori, Tanguay, Simon, Bosse, Dominick, Lalani, Aly-Khan, Bhindi, Bimal, Heng, Daniel, Finelli, Antonio, Fallah-Rad, Nazanin, Castonguay, Vincent, Basappa, Naveen S., Soulières, Denis, Pouliot, Frédéric, Kollmannsberger, Christian, and Bjarnason, Georg A.

Published
2024
Full Text
View/download PDF

3. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

Author

Yang, James Chih-Hsin, Han, Baohui, De La Mora Jiménez, Emmanuel, Lee, Jong-Seok, Koralewski, Piotr, Karadurmus, Nuri, Sugawara, Shunichi, Livi, Lorenzo, Basappa, Naveen S., Quantin, Xavier, Dudnik, Julia, Ortiz, Diego Moran, Mekhail, Tarek, Okpara, Chinyere E., Dutcus, Corina, Zimmer, Zachary, Samkari, Ayman, Bhagwati, Niyati, and Csőszi, Tibor

Published
2024
Full Text
View/download PDF

4. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Author

Sawaya, Ghady Bou-Nehme, Dragomir, Alice, Wood, Lori A., Kollmannsberger, Christian, Basappa, Naveen S., Kapoor, Anil, Soulières, Denis, Finelli, Antonio, Heng, Daniel Y.C., Castonguay, Vincent, Canil, Christina, Winquist, Eric, Graham, Jeffrey, Bjarnason, Georg A., Bhindi, Bimal, Lalani, Aly-Khan, Pouliot, Frédéric, Breau, Rodney H., Saleh, Ramy, and Tanguay, Simon

Published
2024
Full Text
View/download PDF

5. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada

Author

Shayegan, Bobby, Wallis, Christopher J. D., Hamilton, Robert J., Morgan, Scott C., Cagiannos, Ilinas, Basappa, Naveen S., Ferrario, Cristiano., Gotto, Geoffrey T., Fernandes, Ricardo, Roy, Soumyajit, Noonan, Krista L., Niazi, Tamim, Hotte, Sebastien J., Saad, Fred, Hew, Huong, Park-Wyllie, Laura, Chan, Katherine F. Y., and Malone, Shawn

Published
2023
Full Text
View/download PDF

6. Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).

Author

Zarba, Martin, primary, Ferrier, Evan, additional, Wells, Connor, additional, El Zarif, Talal, additional, Basappa, Naveen S., additional, Ebrahimi, Hedyeh, additional, McKay, Rana R., additional, Wood, Lori, additional, Beuselinck, Benoit, additional, Suárez, Cristina, additional, Takemura, Kosuke, additional, Lalani, Aly-Khan A., additional, Li, Haoran, additional, Spain, Lavinia Anne, additional, Templeton, Arnoud J., additional, Powles, Thomas, additional, Bjarnason, Georg A., additional, de Velasco, Guillermo, additional, CHOUEIRI, Toni K., additional, and Heng, Daniel Yick Chin, additional

Published
2024
Full Text
View/download PDF

7. Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens

Author

Saad, Eddy, primary, Gebrael, Georges, additional, Semaan, Karl, additional, Eid, Marc, additional, Saliby, Renée Maria, additional, Labaki, Chris, additional, Sayegh, Nicolas, additional, Wells, J Connor, additional, Takemura, Kosuke, additional, Ernst, Matthew Scott, additional, Lemelin, Audreylie, additional, Basappa, Naveen S, additional, Wood, Lori A, additional, Powles, Thomas, additional, Ernst, D Scott, additional, Lalani, Aly-Khan A, additional, Agarwal, Neeraj, additional, Xie, Wanling, additional, Heng, Daniel Y C, additional, and Choueiri, Toni K, additional

Published
2024
Full Text
View/download PDF

8. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces

Author

Woon, Dixon TS, Chandrasekar, Thenappan, Aaron, Lorne, Basappa, Naveen S, Chi, Kim N, Conter, Henry J, Gotto, Geoffrey, Hotte, Sebastien J, Malone, Shawn, Saad, Fred, Shayegan, Bobby, Park-Wyllie, Laura, and Hamilton, Robert J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prostate Cancer, Urologic Diseases, Good Health and Well Being, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

INTRODUCTION:Treatment using abiraterone acetate plus prednisone, enzalutamide, cabazitaxel, and radium-223 (Ra-223) improves overall survival (OS) and quality of life for patients with metastatic castrate-resistant prostate cancer (mCRPC). Despite their proven benefits, access to these therapies is not equal across Canada. METHODS:We describe provincial differences in access to approved mCRPC therapies. Data sources include the pan-Canadian Oncology Drug Review database, provincial cancer care resources, and correspondence with pharmaceutical companies. RESULTS:Both androgen receptor-axis-targeted therapies (ARATs), abiraterone acetate plus prednisone and enzalutamide, are funded by provinces in the pre-and post-chemotherapy setting, however, sequential ARAT use is not funded. "Sandwich" therapy, where one ARAT is used pre-chemotherapy and a second is used upon progression on chemotherapy, is funded in six provinces: Ontario (ON), Alberta, New Brunswick, Prince Edward Island (PEI), Nova Scotia (NS), and Newfoundland and Labrador. Ra-223 is funded in five provinces: ON, Quebec (QC), British Columbia (BC), Saskatchewan, and Manitoba to varying degrees; ON allows Ra-223 either pre- or post-chemo (not both); QC allows Ra-223 post-chemo unless chemo is not tolerated; BC allows Ra-223 if other life-prolonging mCRPC therapies have been received or ineligible. Cabazitaxel is funded in all provinces post-docetaxel, except QC and PEI. Cabazitaxel is not funded as fist-line treatment for mCPRC or in combination with other agents. In ON, BC, QC, and PEI, cabazitaxel is not funded after progression on an ARAT in the post-chemotherapy setting. CONCLUSIONS:While all provinces have access to docetaxel and ARATs, sandwiching sequential ARATs with docetaxel is funded only in select provinces. Ra-223 and cabazitaxel access is not ubiquitous across Canada. Such inequalities in access to life-prolonging therapies could lead to disparities in survival and quality of life among patients with mCRPC. Further research should quantify interprovincial variation in outcomes and cost that may result from variable access.

Published
2018

9. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients

Author

Thana, Myuran, Basappa, Naveen S., Ghosh, Sunita, Kollmannsberger, Christian K., Heng, Daniel Y.C., Hansen, Aaron R., Graham, Jeffery, Soulières, Denis, Reaume, Martin Neil, Lalani, Aly-Khan A., Castonguay, Vincent, Bjarnason, Georg A., Patenaude, François, Breau, Rodney H., Pouliot, Frédéric, Kapoor, Anil, and Wood, Lori A.

Published
2022
Full Text
View/download PDF

10. Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database.

Author

Park, Changsu Lawrence, Moria, Feras Ayman, Ghosh, Sunita, Wood, Lori, Bjarnason, Georg A., Bhindi, Bimal, Heng, Daniel Yick Chin, Castonguay, Vincent, Pouliot, Frederic, Kollmannsberger, Christian K., Bosse, Dominick, Basappa, Naveen S., Finelli, Antonio, Fallah-rad, Nazanin, Breau, Rodney H., Lalani, Aly-Khan A., Tanguay, Simon, Graham, Jeffrey, and Saleh, Ramy R.

Abstract

Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with mRCC, but its role and timing are not well understood in the era of immunotherapy. The primary objective of this study is to assess outcomes in patients who received ST only, CN followed by ST (CN-ST), and ST followed by CN (ST-CN). The Canadian Kidney Cancer information system (CKCis) database was queried to identify patients with de novo mRCC who received immunotherapy-based ST between January 2014 and June 2023. These patients were classified into three categories as described above. Cox proportional hazards models were used to assess the impact of the timing of ST and CN on overall survival (OS) and progression-free survival (PFS), after adjusting for the International Metastatic RCC Database Consortium (IMDC) risk group, age, and comorbidities. Best overall response and complications of ST and CN for these cohorts were collected. A total of 588 patients were included in this study: 331 patients received ST only, 215 patients received CN-ST, and 42 patients received ST-CN. Patient and disease characteristics including age, gender, performance status, IMDC risk category, comorbidity, histology, type of ST, and metastatic sites are reported. OS analysis favored patients who received ST-CN (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.13–0.68) and CN-ST (HR 0.68, CI 0.47–0.97) over patients who received ST only. PFS analysis showed a similar trend for ST-CN (HR 0.45, CI 0.26–0.77) and CN-ST (HR 0.9, CI 0.68–1.17). This study examined baseline features and outcomes associated with the use and timing of CN and ST using real-world data via a large Canadian real-world cohort. Patients selected to receive CN after ST demonstrated improved outcomes. There were no appreciable differences in perioperative complications across groups. Limitations include the small number of patients in the ST-CN group and residual confounding and selection biases that may influence the outcomes in patients undergoing CN. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Addressing controversial areas in the management of advanced prostate cancer in Canada

Author

Saad, Fred, primary, Hotte, Sebastien J., additional, Noonan, Krista, additional, Malone, Shawn, additional, Morash, Christopher, additional, Niazi, Tamim, additional, Rendon, Ricardo A., additional, Shayegan, Bobby, additional, Basappa, Naveen S., additional, Cagiannos, Ilias, additional, Danielson, Brita, additional, Delouya, Guila, additional, Fernandes, Ricardo, additional, Ferrario, Cristiano, additional, Finelli, Antonio, additional, Gotto, Geoffrey T., additional, Hamilton, Robert J., additional, Izard, Jason P., additional, Kapoor, Anil, additional, Lalani, Aly-Khan, additional, Lavallée, Luke T., additional, Ong, Michael, additional, Pouliot, Frédéric, additional, So, Alan I., additional, Yip, Steven, additional, and Chi, Kim N., additional

Published
2023
Full Text
View/download PDF

13. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Author

Sawaya, Ghady Bou-Nehme, primary, Dragomir, Alice, additional, Wood, Lori A., additional, Kollmannsberger, Christian, additional, Basappa, Naveen S., additional, Kapoor, Anil, additional, Soulières, Denis, additional, Finelli, Antonio, additional, Heng, Daniel Y.C., additional, Castonguay, Vincent, additional, Canil, Christina, additional, Winquist, Eric, additional, Graham, Jeffrey, additional, Bjarnason, Georg A., additional, Bhindi, Bimal, additional, Lalani, Aly-Khan, additional, Pouliot, Frédéric, additional, Breau, Rodney H., additional, Saleh, Ramy, additional, and Tanguay, Simon, additional

Published
2023
Full Text
View/download PDF

14. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

Author

Yang, James Chih-Hsin, primary, Han, Baohui, additional, De La Mora Jiménez, Emmanuel, additional, Lee, Jong-Seok, additional, Koralewski, Piotr, additional, Karadurmus, Nuri, additional, Sugawara, Shunichi, additional, Livi, Lorenzo, additional, Basappa, Naveen S., additional, Quantin, Xavier, additional, Dudnik, Julia, additional, Ortiz, Diego Moran, additional, Mekhail, Tarek, additional, Okpara, Chinyere E., additional, Dutcus, Corina, additional, Zimmer, Zachary, additional, Samkari, Ayman, additional, Bhagwati, Niyati, additional, and Csőszi, Tibor, additional

Published
2023
Full Text
View/download PDF

15. High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors

Author

Zhang, Hanbo, primary, Alimohamed, Nimira S., additional, Basappa, Naveen S., additional, Cheng, Tina, additional, Chu, Michael, additional, Cox-Kennett, Nanette, additional, Ernst, D. Scott, additional, Fontaine, Amelie, additional, Ghosh, Sunita, additional, Heng, Daniel Y.C., additional, Littleton, Richard, additional, North, Scott, additional, Railton, Cindy, additional, Sandhu, Irwindeep, additional, Stenson, Trevor H., additional, Stewart, Douglas A., additional, Venner, Christopher, additional, Venner, Peter C., additional, and Kolinsky, Michael P., additional

Published
2023
Full Text
View/download PDF

16. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Takemura, Kosuke, primary, Ernst, Matthew S., additional, Navani, Vishal, additional, Wells, J. Connor, additional, Bakouny, Ziad, additional, Donskov, Frede, additional, Basappa, Naveen S., additional, Wood, Lori A., additional, Meza, Luis, additional, Pal, Sumanta K., additional, Szabados, Bernadett, additional, Powles, Thomas, additional, Beuselinck, Benoit, additional, McKay, Rana R., additional, Lee, Jae-Lyun, additional, Ernst, D. Scott, additional, Kapoor, Anil, additional, Yuasa, Takeshi, additional, Choueiri, Toni K., additional, and Heng, Daniel Y.C., additional

Published
2023
Full Text
View/download PDF

17. Adjuvant therapy for renal cell carcinoma

Author

Lalani, Aly-Khan A., Kapoor, Anil, Basappa, Naveen S., Bhindi, Bimal, Bjarnason, Georg A., Bosse, Dominick, Breau, Rodney H., Canil, Christina M., Cardenas, Luisa M., Castonguay, Vincent, Chavez-Munoz, Claudia, Chu, William, Dudani, Shaan, Graham, Jeffrey, Heng, Daniel Y.C., Kollmannsberger, Christian, Lattouf, Jean-Baptiste, Morgan, Scott, Reaume, M. Neil, Richard, Patrick O., Swaminath, Anand, Tanguay, Simon, Wood, Lori A., and Lavallée, Luke T.

Subjects
Oncology, Urology, CKCF Consensus Statement
Abstract

INTRODUCTION: Several recent randomized trials evaluated the impact of adjuvant immune checkpoint inhibitor (ICI)-based therapy on post-surgical outcomes in renal cell carcinoma (RCC), with disparate results. The objective of this consensus statement is to provide data-driven guidance regarding the use of ICIs after complete resection of clear-cell RCC in a Canadian context. METHODS: An expert panel of genitourinary medical oncologists, urologic oncologists, and radiation oncologists with expertise in RCC management was convened in a dedicated session during the 2022 Canadian Kidney Cancer Forum in Toronto, Canada. Topic statements on the management of patients after surgery for RCC, including counselling, risk stratification, indications for medical oncology referral, appropriate followup, eligibility and management for adjuvant ICIs, as well as treatment options for patients with recurrence who receive dadjuvant immunotherapy, were discussed. Participants were asked to vote if they agreed or disagreed with each statement. Consensus was achieved if greater than 75% of participants agreed with the topic statement. RESULTS: A total of 22 RCC experts voted on 14 statements. Consensus was achieved on all topic statements. The panel felt patients with clear-cell RCC at increased risk of recurrence after surgery, as per the Keynote-564 group definitions, should be counselled about recurrence risk by a urologist, should be informed about the potential role of adjuvant ICI systemic therapy, and be offered referral to discuss risks and benefits with a medical oncologist. The panel felt that one year of pembrolizumab is currently the only regimen that should be considered if adjuvant therapy is selected. Panelists emphasized current opinions are based on disease-free survival given the available results. Significant uncertainty regarding the benefit and harms of adjuvant therapy remains, primarily due to a lack of consistent benefit observed across similar trials of adjuvant ICI-based therapies and immature overall survival (OS) data. CONCLUSIONS: This consensus document provides guidance from Canadian RCC experts regarding the potential role of ICI-based adjuvant systemic therapy after surgery. This rapidly evolving field requires frequent evidence-based re-evaluation.

Published
2023

18. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

Author

Motzer, Robert J., Choueiri, Toni K., Hutson, Thomas, Young Rha, Sun, Puente, Javier, Lalani, Aly-Khan A., Winquist, Eric, Eto, Masatoshi, Basappa, Naveen S., Tannir, Nizar M., Vaishampayan, Ulka, Bjarnason, Georg A., Oudard, Stéphane, Grünwald, Viktor, Burgents, Joseph, Xie, Ran, McKenzie, Jodi, and Powles, Thomas

Published
2024
Full Text
View/download PDF

19. A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205

Author

Hotte, Sebastien J., Chi, Kim N., Joshua, Anthony M., Tu, Donsheng, Macfarlane, Robyn J., Gregg, Rirchard W., Ruether, Joseph D., Basappa, Naveen S., Finch, Daygen, Salim, Muhammad, Winquist, Eric W., Torri, Vamsee, North, Scott, Kollmannsberger, Christian, Ellard, Susan L., Eigl, Bernard J., Tinker, Anna, Allan, Alison L., Beja, Kevin, Annala, Matti, Powers, Jean, Wyatt, Alexander W., and Seymour, Lesley

Published
2019
Full Text
View/download PDF

20. Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.

Author

Park, Changsu, Ghosh, Sunita, Moria, Feras Ayman, Wood, Lori, Bjarnason, Georg A., Bhindi, Bimal, Heng, Daniel Yick Chin, Castonguay, Vincent, Pouliot, Frederic, Kollmannsberger, Christian K., Bosse, Dominick, Basappa, Naveen S., Finelli, Antonio, Fallah-rad, Nazanin, Breau, Rodney H., Lalani, Aly-Khan A., Tanguay, Simon, Graham, Jeffrey, and Saleh, Ramy R.

Published
2024
Full Text
View/download PDF

21. Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.

Author

Ohm, Hyejee, Ghosh, Sunita, Gupta, Mehul, Wood, Lori, Castonguay, Vincent, Graham, Jeffrey, Kollmannsberger, Christian K., Bosse, Dominick, Soulieres, Denis, Heng, Daniel Yick Chin, Fallah-Rad, Nazanin, Finelli, Antonio, Tanguay, Simon, Lalani, Aly-Khan A., Bhindi, Bimal, Bjarnason, Georg A., Breau, Rodney H., Pouliot, Frederic, and Basappa, Naveen S.

Published
2024
Full Text
View/download PDF

22. Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.

Author

Gupta, Mehul, Wells, Connor, Regan, Meredith M., Xie, Wanling, Navani, Vishal, Saliby, Renee Maria, Basappa, Naveen S., Donskov, Frede, Yuasa, Takeshi, Takemura, Kosuke null, Kollmannsberger, Christian K., Crumbaker, Megan, Lalani, Aly-Khan A., Powles, Thomas, Pal, Sumanta Kumar, McKay, Rana R., Lee, Jae-Lyun, Kanesvaran, Ravindran, Choueiri, Toni K., and Heng, Daniel Yick Chin

Published
2024
Full Text
View/download PDF

23. Management, outcomes and predictors of recurrence in chromophobe renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).

Author

Arenovich, Erica, Breau, Rodney H., Mallick, Ranjeeta, Rendon, Ricardo A., Feifer, Andrew, Pouliot, Frederic, Tanguay, Simon, Lavallee, Luke, Lattouf, Jean-Baptiste, Nayak, Jasmir G., Bhindi, Bimal, Bansal, Rahul K., Finelli, Antonio, Mannas, Miles, Richard, Patrick O., Lalani, Aly-Khan A., Heng, Daniel Yick Chin, Bjarnason, Georg A., Basappa, Naveen S., and Wood, Lori

Published
2024
Full Text
View/download PDF

24. Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.

Author

Beaulieu, Carissa, Ghosh, Sunita, Tajzler, Camilla, Kirkpatrick, McKayla, Castonguay, Vincent, Wood, Lori, Graham, Jeffrey, Soulieres, Denis, Bansal, Rahul K., Heng, Daniel Yick Chin, Finelli, Antonio, Tanguay, Simon, Lalani, Aly-Khan A., Bhindi, Bimal, Bjarnason, Georg A., Breau, Rodney H., and Basappa, Naveen S.

Published
2024
Full Text
View/download PDF

25. Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.

Author

Beltran-Bless, Ana-Alicia, Shani Shrem, Noa, Ghosh, Sunita, Tajzler, Camilla, Wood, Lori, Kollmannsberger, Christian K., Basappa, Naveen S., Graham, Jeffrey, Fallah-rad, Nazanin, Heng, Daniel Yick Chin, Soulieres, Denis, Lalani, Aly-Khan A., Breau, Rodney H., Finelli, Antonio, Tanguay, Simon, Bhindi, Bimal, Bjarnason, Georg A., Pouliot, Frederic, and Canil, Christina M.

Published
2024
Full Text
View/download PDF

26. Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).

Author

Curry, Lauren Caitlin, Ghosh, Sunita, Arenovich, Erica, Tanguay, Simon, Lalani, Aly-Khan A., Heng, Daniel Yick Chin, Bhindi, Bimal, Basappa, Naveen S., Graham, Jeffrey, Bjarnason, Georg A., Breau, Rodney H, Castonguay, Vincent, Soulieres, Denis, Pouliot, Frederic, Bosse, Dominick, Kollmannsberger, Christian K., Finelli, Antonio, Fallah-rad, Nazanin, and Soleimani, Maryam

Published
2024
Full Text
View/download PDF

29. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Takemura, Kosuke, Lemelin, Audreylie, Ernst, Matthew S., Wells, J. Connor, Saliby, Renee Maria, El Zarif, Talal, Labaki, Chris, Basappa, Naveen S., Szabados, Bernadett, Powles, Thomas, Davis, Ian D., Wood, Lori A., Lalani, Aly-Khan A., McKay, Rana R., Lee, Jae-Lyun, Meza, Luis, Pal, Sumanta K., Donskov, Frede, Yuasa, Takeshi, Beuselinck, Benoit, Gebrael, Georges, Agarwal, Neeraj, Choueiri, Toni K., and Heng, Daniel Y.C.

Published
2024
Full Text
View/download PDF

30. Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population

Author

Millan, Braden, primary, Breau, Rodney H., additional, Mallick, Ranjeeta, additional, Wood, Lori, additional, Rendon, Ricardo, additional, Finelli, Antonio, additional, So, Alan I., additional, Lavallée, Luke T., additional, Pouliot, Frédéric, additional, Bhindi, Bimal, additional, Heng, Daniel, additional, Drachenberg, Darrel, additional, Tanguay, Simon, additional, Dean, Lucas, additional, Basappa, Naveen S., additional, Lattouf, Jean-Baptiste, additional, Bjarnason, George, additional, Lalani, Aly-Khan, additional, and Kapoor, Anil, additional

Published
2023
Full Text
View/download PDF

31. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Author

Choueiri, Toni K, primary, Eto, Masatoshi, additional, Motzer, Robert, additional, De Giorgi, Ugo, additional, Buchler, Tomas, additional, Basappa, Naveen S, additional, Méndez-Vidal, María José, additional, Tjulandin, Sergei, additional, Hoon Park, Se, additional, Melichar, Bohuslav, additional, Hutson, Thomas, additional, Alemany, Carlos, additional, McGregor, Bradley, additional, Powles, Thomas, additional, Grünwald, Viktor, additional, Alekseev, Boris, additional, Rha, Sun Young, additional, Kopyltsov, Evgeny, additional, Kapoor, Anil, additional, Alonso Gordoa, Teresa, additional, Goh, Jeffrey C, additional, Staehler, Michael, additional, Merchan, Jaime R, additional, Xie, Ran, additional, Perini, Rodolfo F, additional, Mody, Kalgi, additional, McKenzie, Jodi, additional, and Porta, Camillo G, additional

Published
2023
Full Text
View/download PDF

32. Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Author

Takemura, Kosuke, primary, Lemelin, Audreylie, additional, Ernst, Matthew Scott, additional, Wells, Connor, additional, Basappa, Naveen S., additional, Szabados, Bernadett, additional, Powles, Thomas, additional, Davis, Ian D., additional, Wood, Lori, additional, Kapoor, Anil, additional, McKay, Rana R., additional, Lee, Jae-Lyun, additional, Meza, Luis A, additional, Pal, Sumanta Monty, additional, Donskov, Frede, additional, Yuasa, Takeshi, additional, Beuselinck, Benoit, additional, Gebrael, Georges, additional, Choueiri, Toni K., additional, and Heng, Daniel Yick Chin, additional

Published
2023
Full Text
View/download PDF

34. Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.

Author

Labaki, Chris, primary, Bakouny, Ziad, additional, Wells, J Connor, additional, Takemura, Kosuke, additional, Saliby, Renee Maria, additional, Meza, Luis A, additional, Gebrael, Georges, additional, Porta, Camillo, additional, Lee, Jae-Lyun, additional, Basappa, Naveen S., additional, De Velasco, Guillermo, additional, McKay, Rana R., additional, Pal, Sumanta Monty, additional, Agarwal, Neeraj, additional, Donskov, Frede, additional, Braun, David A., additional, Henske, Elizabeth, additional, Xie, Wanling, additional, Heng, Daniel Yick Chin, additional, and Choueiri, Toni K., additional

Published
2023
Full Text
View/download PDF

35. Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Author

Gotto, Geoffrey T., primary, Yip, Steven M., additional, Shayegan, Bobby, additional, O'Sullivan, Dylan E., additional, Wallis, Christopher J.D., additional, Basappa, Naveen S., additional, Cagiannos, Ilias, additional, Hamilton, Robert James, additional, Ferrario, Cristiano, additional, Fernandes, Ricardo, additional, Danielson, Brita, additional, Saad, Fred, additional, Hotte, Sebastien J., additional, Brenner, Darren R., additional, Cheung, Winson Y., additional, Boyne, Devon J., additional, Chan, Katherine, additional, Osborne, Brendan, additional, Zardan, Anousheh, additional, and Malone, Shawn, additional

Published
2023
Full Text
View/download PDF

37. Outcomes of partial nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian multi-institutional collaborative.

Author

Bansal, Rahul K., primary, Cassim, Raees, additional, Sun, Ryan, additional, Mallick, Ranjeeta, additional, Finelli, Antonio, additional, Tanguay, Simon, additional, Drachenberg, Darrel E, additional, Pouliot, Frederic, additional, Lavallee, Luke, additional, So, Alan I., additional, Rendon, Ricardo A., additional, Wood, Lori, additional, Kapoor, Anil, additional, Lalani, Aly-Khan A., additional, Basappa, Naveen S., additional, Bhindi, Bimal, additional, Dean, Lucas W., additional, Bjarnason, Georg A., additional, and Breau, Rodney H., additional

Published
2023
Full Text
View/download PDF

38. Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

Author

Lemelin, Audreylie, primary, Ernst, Matthew Scott, additional, Wells, Connor, additional, Navani, Vishal, additional, McGregor, Bradley Alexander, additional, Wong, Shirley S., additional, Pal, Sumanta Monty, additional, Basappa, Naveen S., additional, Kapoor, Anil, additional, Lee, Jae-Lyun, additional, Donskov, Frede, additional, Li, Haoran, additional, Yuasa, Takeshi, additional, Chang, Rose, additional, Huynh, Lynn, additional, Nguyen, Catherine, additional, Holub, Ashley, additional, Clear, Louise, additional, Duh, Mei Sheng, additional, and Heng, Daniel Yick Chin, additional

Published
2023
Full Text
View/download PDF

39. Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

Author

Lalani, Aly-Khan A., primary, Swaminath, Anand, additional, Pond, Gregory Russell, additional, Morgan, Scott C., additional, Azad, Arun, additional, Chu, William, additional, Kapoor, Anil, additional, Bonert, Michael, additional, Bramson, Jonathan L., additional, Surette, Michael G., additional, Bosse, Dominick, additional, Siva, Shankar, additional, Bjarnason, Georg A., additional, Gopaul, Darin, additional, Basappa, Naveen S., additional, Wright, Jim, additional, and Hotte, Sebastien J., additional

Published
2023
Full Text
View/download PDF

40. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Takemura, Kosuke, primary, Navani, Vishal, additional, Ernst, Matthew S., additional, Wells, J. Connor, additional, Meza, Luis, additional, Pal, Sumanta K., additional, Lee, Jae-Lyun, additional, Li, Haoran, additional, Agarwal, Neeraj, additional, Alva, Ajjai S., additional, Hansen, Aaron R., additional, Basappa, Naveen S., additional, Szabados, Bernadett, additional, Powles, Thomas, additional, Tran, Ben, additional, Hocking, Christopher M., additional, Beuselinck, Benoit, additional, Yuasa, Takeshi, additional, Choueiri, Toni K., additional, and Heng, Daniel Y. C., additional

Published
2022
Full Text
View/download PDF

41. Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma

Author

Parmar, Ambica, primary, Ghosh, Sunita, additional, Sahgal, Arjun, additional, Lalani, Aly‐Khan A., additional, Hansen, Aaron R., additional, Reaume, M. Neil, additional, Wood, Lori, additional, Basappa, Naveen S., additional, Heng, Daniel Y. C., additional, Graham, Jeffrey, additional, Kollmannsberger, Christian, additional, Soulières, Denis, additional, Breau, Rodney H., additional, Tanguay, Simon, additional, Kapoor, Anil, additional, Pouliot, Frédéric, additional, and Bjarnason, Georg A., additional

Published
2022
Full Text
View/download PDF

42. A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System

Author

Millan, Braden, primary, Breau, Rodney H., additional, Bhindi, Bimal, additional, Mallick, Ranjeeta, additional, Tanguay, Simon, additional, Finelli, Antonio, additional, Lavallée, Luke T., additional, Pouliot, Frédéric, additional, Rendon, Ricardo, additional, So, Alan I., additional, Dean, Lucas, additional, Lattouf, Jean-Baptiste, additional, Basappa, Naveen S., additional, and Kapoor, Anil, additional

Published
2022
Full Text
View/download PDF

44. Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System

Author

Nguyen, Eric K., primary, Lalani, Aly Khan A., additional, Ghosh, Sunita, additional, Basappa, Naveen S., additional, Kapoor, Anil, additional, Hansen, Aaron R., additional, Kollmannsberger, Christian, additional, Heng, Daniel, additional, Wood, Lori A., additional, Castonguay, Vincent, additional, Soulières, Denis, additional, Winquist, Eric, additional, Canil, Christina, additional, Graham, Jeffrey, additional, Bjarnason, Georg A., additional, Breau, Rodney H., additional, Pouliot, Frédéric, additional, and Swaminath, Anand, additional

Published
2022
Full Text
View/download PDF

45. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.

Author

Kosuke Takemura, Navani, Vishal, Ernst, Matthew S., Wells, J. Connor, Meza, Luis, Pal, Sumanta K., Jae-Lyun Lee, Li, Haoran, Agarwal, Neeraj, Alva, Ajjai S., Hansen, Aaron R., Basappa, Naveen S., Szabados, Bernadett, Powles, Thomas, Tran, Ben, Hocking, Christopher M., Beuselinck, Benoit, Takeshi Yuasa, Choueiri, Toni K., and Heng, Daniel Y. C.

Subjects
RENAL cell carcinoma, PROTEIN-tyrosine kinase inhibitors, DATABASES, VASCULAR endothelial growth factors
Abstract

Purpose: Clinical trials have demonstrated higher complete response rates in the immuno-oncologye based combination arms than in the tyrosine kinase inhibitor arms in patients with metastatic renal cell carcinoma. We aimed to characterize real-world patients who experienced complete response to the contemporary first-line therapies. Materials and Methods: Using the International Metastatic Renal Cell Carcinoma Database Consortium, response-evaluable patients who received frontline immuno-oncologye based combination therapy or tyrosine kinase inhibitor monotherapy were analyzed. Baseline characteristics of patients and post-landmark overall survival were compared based on best overall response, as per RECIST 1.1. Results: A total of 52 (4.6%) of 1,126 and 223 (3.0%) of 7,557 patients experienced complete response to immuno-oncologye based and tyrosine kinase inhibitor therapies, respectively (P [ .005). An adjusted odds ratio for complete response achieved by immuno-oncologye based combination therapy (vs tyrosine kinase inhibitor monotherapy) was 1.56 (95% CI 1.11-2.17; P [ .009). Among patients who experienced complete response, the immuno-oncologye based cohort had a higher proportion of noneclear cell histology (15.9% and 4.7%; P [ .016), sarcomatoid dedifferentiation (29.8% and 13.5%; P [ .014), and multiple sites of metastases (80.4% and 50.0%; P < .001) than the tyrosine kinase inhibitor cohort. Complete response was independently associated with post-landmark overall survival benefit in both the immuno-oncologye based and tyrosine kinase inhibitor cohorts, giving respective adjusted hazard ratios of 0.17 (95% CI 0.04-0.72; P [ .016) and 0.28 (95% CI 0.21-0.38; P < .001). Conclusions: The complete response rate was not as high in the real-world population as in the clinical trial population. Among those who experienced complete response, several adverse clinicopathological features were more frequently observed in the immuno-oncologye based cohort than in the tyrosine kinase inhibitor cohort. Complete response was an indicator of favorable overall survival. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

Author

Navani, Vishal, primary, Ernst, Matthew, additional, Wells, J. Connor, additional, Yuasa, Takeshi, additional, Takemura, Kosuke, additional, Donskov, Frede, additional, Basappa, Naveen S., additional, Schmidt, Andrew, additional, Pal, Sumanta K., additional, Meza, Luis, additional, Wood, Lori A., additional, Ernst, D. Scott, additional, Szabados, Bernadett, additional, Powles, Thomas, additional, McKay, Rana R., additional, Weickhardt, Andrew, additional, Suarez, Cristina, additional, Kapoor, Anil, additional, Lee, Jae Lyun, additional, Choueiri, Toni K., additional, and Heng, Daniel Y. C., additional

Published
2022
Full Text
View/download PDF

47. Patterns of care for non‐metastatic castration‐resistant prostate cancer: A population‐based study

Author

Malone, Shawn, primary, Wallis, Christopher J. D., additional, Lee‐Ying, Richard, additional, Basappa, Naveen S., additional, Cagiannos, Ilias, additional, Hamilton, Robert J., additional, Fernandes, Ricardo, additional, Ferrario, Cristiano, additional, Gotto, Geoffrey T., additional, Morgan, Scott C., additional, Morash, Christopher, additional, Niazi, Tamim, additional, Noonan, Krista L., additional, Rendon, Ricardo, additional, Hotte, Sebastien J., additional, Saad, Fred, additional, Zardan, Anousheh, additional, Osborne, Brendan, additional, Chan, Katherine F. Y., additional, and Shayegan, Bobby, additional

Published
2022
Full Text
View/download PDF

48. sj-docx-1-tam-10.1177_17588359221108685 – Supplemental material for Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Author

Lalani, Aly-Khan A., Heng, Daniel Y. C., Basappa, Naveen S., Wood, Lori, Iqbal, Nayyer, McLeod, Deanna, Soulières, Denis, and Kollmannsberger, Christian

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359221108685 for Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review by Aly-Khan A. Lalani, Daniel Y. C. Heng, Naveen S. Basappa, Lori Wood, Nayyer Iqbal, Deanna McLeod, Denis Soulières and Christian Kollmannsberger in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

49. sj-docx-2-tam-10.1177_17588359221108685 – Supplemental material for Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Author

Lalani, Aly-Khan A., Heng, Daniel Y. C., Basappa, Naveen S., Wood, Lori, Iqbal, Nayyer, McLeod, Deanna, Soulières, Denis, and Kollmannsberger, Christian

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tam-10.1177_17588359221108685 for Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review by Aly-Khan A. Lalani, Daniel Y. C. Heng, Naveen S. Basappa, Lori Wood, Nayyer Iqbal, Deanna McLeod, Denis Soulières and Christian Kollmannsberger in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results